tbuckley/cabot-search huggingface dataset:
Non-tuberculous mycobacterial pulmonary disease
Authors: Steven Cowman, Jakko van Ingen, David E. Griffith, Michael R. Loebinger
Journal: European Respiratory Journal (2019)

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a challenging infection which is becoming increasingly prevalent, particularly in the elderly, for reasons which are unknown. While underlying lung disease is a well-established risk factor for NTM-PD, it may also occur in apparently healthy individuals. No single common genetic or immunological defect has been identified in this group, and it is likely that multiple pathways contribute towards host susceptibility to NTM-PD which further interact with environmental and microbiological factors leading to the development of disease. The diagnosis of NTM-PD relies on the integration of clinical, radiological and microbiological results. The clinical course of NTM-PD is heterogeneous, with some patients remaining stable without the need for treatment and others developing refractory disease associated with considerable mortality and morbidity. Treatment regimens are based on the identity of the isolated species, drug sensitivity testing (for some agents) and the severity of disease. Multiple antibiotics are typically required for prolonged periods of time and treatment is frequently poorly tolerated. Surgery may be beneficial in selected cases. In some circumstances cure may not be attainable and there is a pressing need for better regimens to treat refractory and drug-resistant NTM-PD. This review summarises current knowledge on the epidemiology, aetiology and diagnosis of NTM-PD and discusses the treatment of two of the most clinically significant species, the M. avium and M. abscessus complexes, with a focus on refractory disease and novel therapies.
Current Practice of Hospital Acquired Thrombosis (HAT) Prevention in an Acute Hospital (a single centre cross sectional study)
Authors: Dr. Muhammad Irfan Khan, Catriona O'Leary, Mary Ann Hayes, Patricia O'Flynn, Pauline Suzanne Chappell, Dympna Kiely Hinchion, Dr. Anila Laurence, Dr. Usman Azhar Khan, Dr. Akbar Amin Achakzai, Dr. Shahid Ali Kaimkhani, Dr. Mary McCarthy, Dr. Maire Rafferty, Siobhan Rafferty, Dr. Naveed Khan, Dr. Lorraine Thong, Denise Leamy, Fiona Ahern, Virginia Silvari, Mala Shah, Amy O'Flynn, Prof. Joe Eustace, Dr. Sada Sulong, Dr. Cleona Duggan, Dr. Susan O'Shea
Journal: Blood (2015)
Role of PDGF/PDGFR in Regulation of Thrombopoiesis: A Possible Explanation for Imatinib Mesylate-Induced Thrombocytopenia in the Treatment of CML
Authors: Mo Yang, Fanyi Meng, Jie yu Ye, Yue Xu, Bin Xiao, Beng Chong
Journal: Blood (2012)
Pilot Study of Peginterferon Alfa-2a (PEGASYS®) Concurrent Administration during Induction Chemoradiotherapy and Maintenance Therapy in Patients with EBV-Associated Extranodal NK/T Cell Lymphoma
Authors: Seok-Goo Cho, Sung-Won Kim, Kyung-Sin Park, Ji-Hyang Lim, Chang-Ki Min, Yong-Goo Kim, Jong-Wook Lee, Woo-Sung Min
Journal: Blood (2008)
Change of Practice Patterns and Outcomes of Vena Cava Filters in Korean Patients: Multicenter, Retrospective Analysis
Authors: Sung Hyun Kim, Jimin Choi, Yeo-Kyeoung Kim, Moon Ju Jang, Ho-Young Yhim, Soo-Mee Bang, Won-Il Choi, Doyeun Oh
Journal: Blood (2011)
Management of Refractory Intracranial Hemorrhage in a Coagulopathic Patient with Liver Disease by Using Recombinant Factor VIIa (rFVIIa).
Authors: Goksel Leblebisatan, Ilgen Sasmaz, Kurthan Mert, Ebru Ozates, Bulent Antmen, Yurdanur Kilinc
Journal: Blood (2005)
Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.
Authors: Madeleine Duvic, Youn Kim, Sunil Reddy, Andres Forero-Torres, Lauren C. Pinter-Brown, Mark U. Rarick, John Zic, Sophie Worobec, Neil Korman, Timothy Kuzel, Kimberly Bohjanen, Karen Flessland, Jeremy Barton, Eric Sievers
Journal: Blood (2006)
The Lectin-Like Domain of Thrombomodulin Protects Against Diabetic Nephropathy by Inhibiting Complement Activation
Authors: Hongjie Wang, Ilya Vinnikov, Qianxing Zhou, Thati Madhusudhan, Khurrum Shahzad, Muhammed Kashif, Juliane Wolter, Angelika Bierhaus, Peter Nawroth, Edward M. Conway, Berend Isermann
Journal: Blood (2010)
CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease
Authors: Sarah E. May, Adam Kashishian, Thomas S. Lin, Jeffrey A. Jones, Joseph M. Flynn, Roger G. Ulrich, Hao Chen, Albert S. Yu, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, John C. Byrd, Amy J. Johnson
Journal: Blood (2008)
ATIM-25. TEN-YEAR FOLLOW UP WITH LONG TERM REMISSION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ICT-107 VACCINE (PHASE I)
Authors: Surasak Phuphanich, Christopher Wheeler, Jeremy Rudnick, Jethro Hu, Mia Mazer, Cherry Sanchez, Miriam Nuno, Ray Chu, Keith Black, John Yu
Journal: Neuro-Oncology (2016)

We previously reported 7 patients with prolonged survival > 5 years from a phase I study of 16 newly diagnosed GBM patients (Neuro-Oncology 15(suppl3), 71, IT-015, 2013) and expression of four ICT-107 targeted antigens in pre-immunotherapy tumors correlated with prolonged OS and PFS in GBM patients (Cancer Immunol Immunother. 2013 Jan;62(1):125-35. ICT-107 is an autologous immunotherapy consisting of patient dendritic cells pulsed with six tumor associated peptides (TAA) peptides derived from AIM-2, TRP-2, HER2/neu, IL-13Ra2 (overexpressed on CSC), gp100, MAGE1 administered intradermal three times at two week intervals to HLA-A1 and/or HLA-A2 positive GBM patients after a standard therapy with concurrent Temozolomide and radiation therapy. With 10-year follow up, we identified 3(19%) of 16 the GBM patients were disease free over 8 years (PFS 9.2+, 8.3+, 8.1+) and 6 patients (KPS 90%, age range 34-62 years old at age of diagnosis) survived > 7.7 years (range 7.7- 9.6 years). There were 2 HLA-A1+ and 4 HLA-A2+ and their TAA expressed at least 5 peptides including antigens overexpressed on CSC in this group. One patient with PFS >9.2 years is working full time with good quality of life, showed immune response 2.5 (>1.5 fold increase IFNg production after administration by tetramer/FACS). Six (38%) of 16 GBM patients are presently alive > 7.7 years and only one patient received active treatment for recurrence. While long term remission and survival was seen in this 16 GBM patient cohort, median PFS was 16.9 months, 5-year PFS was 37.5% (95%:15.4-60), median OS was 38.4 months and 5-year OS rate was 50% (95% CI: 24.5-71). It is unprecedented to have 19% long term remission > 8 years in this group from ICT-107 immunotherapy. This correlated with cancer-stem-associated expression, and a trend toward greater CD8 T cell cytokine responses.
Prospective Multicenter Phase II Study of Myeloablative Conditioning Consisted of Intravenous Busulfan and Fludarabine +/− Total Body Irradiation for Older Patients (55 years and older): Results of the JSCT FB09 Study.
Authors: Naoyuki Uchida, Michihiro Hidaka, Toru Sakura, Toshihiro Miyamoto, Tomoaki Fujisaki, Tetsuya Eto, Yoshinobu Maeda, Kenji Fukuno, Kana Matsumoto, Kunihiko Morita, Junji Kishimoto, Takahiro Fukuda, Takanori Teshima, Shuichi Taniguchi, Shin-Ichiro Mori, Mine Harada
Journal: Blood (2010)
A Pilot Study To Evaluate the Safety, Efficacy and Effects on Liver Function of Granulocyte Colony-Stimulating Factor To Mobilize Hematopoietic Stem Cells in Patients with Liver Cirrhosis.
Authors: Alessandro Isidori, Lucia Catani, Simona Talarico, Stefania Lorenzini, Elisabetta Loggi, Annagiulia Gramenzi, Francesca Bonifazi, Michela Aluigi, Mauro Bernardi, Pietro Andreone, Michele Baccarani, Roberto M. Lemoli
Journal: Blood (2005)
Treatment of hidradenitis suppurativa
Journal: JAMA (1973)

<h3>To the Editor.—</h3> I would like to agree wholeheartedly with early operative treatment. However, I do not think grafting is indicated except in rare circumstances. If one excises abscesses and cysts, as they appear, going deep into the fat and making certain that all apocrine gland tissue is removed, then grafting will be unnecessary. The wounds can either be left to heal by secondary intention or can be primarily sutured. With proper placement of incision, and with time, surprisingly little or no limitation of movement is encountered. This treatment is simpler than grafting, yields the same results, and does not result in the emotional trauma to the patient in having a recurrence beneath or at the edge of a graft, which we have seen all too often in patients who have had grafts. I would like to repeat, however, that definitive treatment should never consist of merely incision and drainage
Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation
Authors: Norihiro Ueda, Yasusi Uemura, Rhong Zhang, Shuichi Kitayama, Yutaka Yasui, Minako Tatsumi, Tian-Yi Liu, Kiyotaka Kuzushima, Hitoshi Kiyoi, Tomoki Naoe, Shin Kaneko
Journal: Blood (2015)
Osteonecrosis of the Jaw Associated with Chronic Bisphosphonates Therapy: An Italian Experience.
Authors: Anna M. Cafro, Luciana A. Barbarano, Alessandro Andriani, Giovanna D’Avanzo, Michele Nichelatti, Domenico Gaglioti, Alberto Taroni, Livio Gargantini, Michela G. Draisci, Enrica Morra
Journal: Blood (2005)
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Authors: Koichi Takahashi, Feng Wang, Hagop Kantarjian, Denaha Doss, Kanhav Khanna, Erika Thompson, Li Zhao, Keyur Patel, Sattva Neelapu, Curtis Gumbs, Carlos Bueso-Ramos, Courtney D DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xuelin Huang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia-Manero, P Andrew Futreal
Journal: The Lancet Oncology (2016)
LP29 : A randomised prospective open-label trial comparing peginterferon + adefovir and peginterferon + tenofovir versus no treatment in hbeag negative chronic hepatitis b patients with low viral load: analysis of week 48 results
Authors: A. de Niet, L. Jansen, F. Stelma, S.B. Willemse, S.D. Kuiken, S. Weijer, K.M. van Nieuwkerk, H.L. Zaaijer, R. Molenkamp, R.B. Takkenberg, M. Koot, J. Verheij, U. Beuers, H.W. Reesink
Journal: Journal of Hepatology (2015)
A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis
Authors: Erin Peckham, Philip J Lupo, Michael E Scheurer, Rikhia Chakraborty, John Belmont, Spiridon Tsavachidis, Albert Shih, Harshal Abhyankar, Karen Phaik Har Lim, Brooks Scull, Kenneth L. McClain, Carl Allen
Journal: Blood (2015)
Glutamatergic synaptic integration of locomotion speed via septoentorhinal projections
Authors: Daniel Justus, Dennis Dalügge, Stefanie Bothe, Falko Fuhrmann, Christian Hannes, Hiroshi Kaneko, Detlef Friedrichs, Liudmila Sosulina, Inna Schwarz, David Anthony Elliott, Susanne Schoch, Frank Bradke, Martin Karl Schwarz, Stefan Remy
Journal: Nature Neuroscience (2016)
HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma
Authors: Mamta Gupta, Jing Jing Han, Mary Stenson, Linda Wellik, Thomas E. Witzig
Journal: Blood (2010)
Variation in<i>PCSK9</i>and<i>HMGCR</i>and Risk of Cardiovascular Disease and Diabetes
Authors: Brian A. Ference, Jennifer G. Robinson, Robert D. Brook, Alberico L. Catapano, M. John Chapman, David R. Neff, Szilard Voros, Robert P. Giugliano, George Davey Smith, Sergio Fazio, Marc S. Sabatine
Journal: New England Journal of Medicine (2016)

Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown.We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes.Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes.In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Enumeration of Peripheral Blood Hematopoietic Stem Cells Using Automated Hematology Analyzer, Sysmex-XN: Final Resutls of Multicenter Prospective Study
Authors: Ryuji Tanosaki, Yoshiki Okuyama, Tohru Iseki, Makoto Handa, Shuichi Kino, Katsuya Ikuta, Shigehisa Yoshida, Kyoko Haraguchi, Naomi Shimizu, Shio Sakai, Naohide Watanabe, Tomoe Uemura, Yoshie Kawahara, Kazuo Muroi, Tokiko Nagamura-Inoue, Minoko Takanashi
Journal: Blood (2015)
PGE2-Independent Expression of Indoleamine 2,3-Dioxygenase-2 (IDO2) Supports the Tolerogenic Function of Monocyte-Derived Dendritic Cells,
Authors: Sara Trabanelli, Antonio Curti, Darina Ocadlikova, Cecilia Evangelisti, Valentina Salvestrini, Marilena Ciciarello, Michela Aluigi, Lara Rossi, Richard Metz, Lisa Laury-Kleintop, George Prendergast, Roberto M. Lemoli
Journal: Blood (2011)
Cytohesin 1 regulates homing and engraftment of human hematopoietic stem and progenitor cells
Authors: Justyna Rak, Katie Foster, Katarzyna Potrzebowska, Mehrnaz Safaee Talkhoncheh, Natsumi Miharada, Karolina Komorowska, Therese Torngren, Anders Kvist, Åke Borg, Lena Svensson, Dominique Bonnet, Jonas Larsson
Journal: Blood (2016)
A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012
Authors: Kenneth M. Langa, Eric B. Larson, Eileen M. Crimmins, Jessica D. Faul, Deborah A. Levine, Mohammed U. Kabeto, David R. Weir
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> The aging of the US population is expected to lead to a large increase in the number of adults with dementia, but some recent studies in the United States and other high-income countries suggest that the age-specific risk of dementia may have declined over the past 25 years. Clarifying current and future population trends in dementia prevalence and risk has important implications for patients, families, and government programs. <h3>Objective</h3> To compare the prevalence of dementia in the United States in 2000 and 2012. <h3>Design, Setting, and Participants</h3> We used data from the Health and Retirement Study (HRS), a nationally representative, population-based longitudinal survey of individuals in the United States 65 years or older from the 2000 (n = 10 546) and 2012 (n = 10 511) waves of the HRS. <h3>Main Outcomes and Measures</h3> Dementia was identified in each year using HRS cognitive measures and validated methods for classifying self-respondents, as well as those represented by a proxy. Logistic regression was used to identify socioeconomic and health variables associated with change in dementia prevalence between 2000 and 2012. <h3>Results</h3> The study cohorts had an average age of 75.0 years (95% CI, 74.8-75.2 years) in 2000 and 74.8 years (95% CI, 74.5-75.1 years) in 2012 (<i>P </i>= .24); 58.4% (95% CI, 57.3%-59.4%) of the 2000 cohort was female compared with 56.3% (95% CI, 55.5%-57.0%) of the 2012 cohort (<i>P </i>&lt; .001). Dementia prevalence among those 65 years or older decreased from 11.6% (95% CI, 10.7%-12.7%) in 2000 to 8.8% (95% CI, 8.2%-9.4%) (8.6% with age- and sex-standardization) in 2012 (<i>P</i> &lt; .001). More years of education was associated with a lower risk for dementia, and average years of education increased significantly (from 11.8 years [95% CI, 11.6-11.9 years] to 12.7 years [95% CI, 12.6-12.9 years];<i>P</i> &lt; .001) between 2000 and 2012. The decline in dementia prevalence occurred even though there was a significant age- and sex-adjusted increase between years in the cardiovascular risk profile (eg, prevalence of hypertension, diabetes, and obesity) among older US adults. <h3>Conclusions and Relevance</h3> The prevalence of dementia in the United States declined significantly between 2000 and 2012. An increase in educational attainment was associated with some of the decline in dementia prevalence, but the full set of social, behavioral, and medical factors contributing to the decline is still uncertain. Continued monitoring of trends in dementia incidence and prevalence will be important for better gauging the full future societal impact of dementia as the number of older adults increases in the decades ahead.
Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy
Authors: Adam S. Helms, Francisco J. Alvarado, Jaime Yob, Vi T. Tang, Francis Pagani, Mark W. Russell, Héctor H. Valdivia, Sharlene M. Day
Journal: Circulation (2016)

Aberrant calcium signaling may contribute to arrhythmias and adverse remodeling in hypertrophic cardiomyopathy (HCM). Mutations in sarcomere genes may distinctly alter calcium handling pathways.We analyzed gene expression, protein levels, and functional assays for calcium regulatory pathways in human HCM surgical samples with (n=25) and without (n=10) sarcomere mutations compared with control hearts (n=8).Gene expression and protein levels for calsequestrin, L-type calcium channel, sodium-calcium exchanger, phospholamban, calcineurin, and calcium/calmodulin-dependent protein kinase type II (CaMKII) were similar in HCM samples compared with controls. CaMKII protein abundance was increased only in sarcomere-mutation HCM (P<0.001). The CaMKII target pT17-phospholamban was 5.5-fold increased only in sarcomere-mutation HCM (P=0.01), as was autophosphorylated CaMKII (P<0.01), suggestive of constitutive activation. Calcineurin (PPP3CB) mRNA was not increased, nor was RCAN1 mRNA level, indicating a lack of calcineurin activation. Furthermore, myocyte enhancer factor 2 and nuclear factor of activated T cell transcription factor activity was not increased in HCM, suggesting that calcineurin pathway activation is not an upstream cause of increased CAMKII protein abundance or activation. SERCA2A mRNA transcript levels were reduced in HCM regardless of genotype, as was sarcoplasmic endoplasmic reticular calcium ATPase 2/phospholamban protein ratio (45% reduced; P=0.03). 45Ca sarcoplasmic endoplasmic reticular calcium ATPaseuptake assay showed reduced uptake velocity in HCM regardless of genotype (P=0.01). The cardiac ryanodine receptor was not altered in transcript, protein, or phosphorylated (pS2808, pS2814) protein abundance, and [3H]ryanodine binding was not different in HCM, consistent with no major modification of the ryanodine receptor.Human HCM demonstrates calcium mishandling through both genotype-specific and common pathways. Posttranslational activation of the CaMKII pathway is specific to sarcomere mutation-positive HCM, whereas sarcoplasmic endoplasmic reticular calcium ATPase 2 abundance and sarcoplasmic reticulum Ca uptake are depressed in both sarcomere mutation-positive and -negative HCM.
Anatomical Distribution of First VTE Event and Risk of VTE Recurrence: Long Term Follow-up and Retrospective Analysis of 346 Patients. Experience From a Single Center
Authors: Emmanouil Papadakis, Dionysia Theocharidou, Anastasia Mpanti, Anastasia Spyrou, Konstantinos Loukidis, Konstantinos Tsepanis, Anna Karagianni, Vaia Papageorgiou, Anna Kioumi, Ioannis Korantzis
Journal: Blood (2011)
Opioids and adverse outcomes in elderly chronic obstructive pulmonary disease patients
Authors: Damien Viglino, Maxime Maignan
Journal: European Respiratory Journal (2016)

We read with interest the study by Vozoris et al . [1] describing the risk of adverse outcomes associated with opioid use in elderly chronic obstructive pulmonary disease (COPD) patients. There is currently a strong debate on the prescription of opioids in patients with COPD. While several studies seemed to demonstrate the harmlessness of opioids in this population [2–4], two recent studies including the one by Vozoris et al . [1] challenge this result [5]. The large number of included patients and the excellent method used in these two studies strongly support the idea of an excess morbidity or mortality associated with the opioid use in COPD patients. There is, however, one limitation that needs to be taken into consideration. Opioids in patients with COPD: results of mortality should be interpreted with caution regarding exclusion criteria <http://ow.ly/IJbd304nC36>
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Authors: Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley, Rebecca S Kristeleit, Ling Ma, Katherine M Bell-McGuinn, James D Brenton, Janiel M Cragun, Ana Oaknin, Isabelle Ray-Coquard, Maria I Harrell, Elaina Mann, Scott H Kaufmann, Anne Floquet, Alexandra Leary, Thomas C Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A McNeish
Journal: The Lancet Oncology (2016)